Comparative Pharmacology
Head-to-head clinical analysis: DASETTA 7 7 7 versus PIRMELLA 1 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DASETTA 7 7 7 versus PIRMELLA 1 35.
DASETTA 7/7/7 vs PIRMELLA 1/35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DASETTA 7/7/7 contains drospirenone and ethinyl estradiol. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity; ethinyl estradiol is an estrogen. The primary mechanism is inhibition of gonadotropin secretion (FSH, LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation. Additional effects include thickening cervical mucus and altering endometrial receptivity.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that suppresses gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Additionally, causes cervical mucus thickening and endometrial atrophy, reducing sperm penetration and implantation.
One tablet orally three times daily at 7-hour intervals (7:00 AM, 2:00 PM, 9:00 PM). Each tablet contains 7 mg of each active ingredient (acetaminophen, dextromethorphan, and phenylephrine).
One tablet orally once daily for 21 days, followed by 7 placebo tablets during the withdrawal bleed.
None Documented
None Documented
The terminal elimination half-life is approximately 4-6 hours in patients with normal renal function. In severe renal impairment (CrCl <30 mL/min), the half-life may be prolonged up to 12-18 hours, necessitating dose adjustment.
Terminal half-life 24–30 hours for ethinyl estradiol; 13–18 hours for norethindrone. Steady state reached after 7–10 days.
DASETTA 7/7/7 is excreted primarily via the kidneys (85-90% as unchanged drug), with approximately 10-15% eliminated in feces via biliary excretion. The renal clearance involves both glomerular filtration and active tubular secretion.
Renal 60–80% as metabolites (glucuronide conjugates), biliary/fecal 10–20%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive